Novartis will construct a $700 million biotech manufacturing facility in the Singapore’s Tuas Biomedical Park. The plant will contain Novartis’ seventh – and largest – bioreactor worldwide. Once open, the new facility will employ 300 people. Construction will begin next year, with completion (and certification) expected in 2012. The facility will provide both clinical and commercial supplies of new biopharma drugs, which are increasingly important to Novartis.  More details...

Stock Symbol: (NYSE: NVS)